Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Trial of Direct Administration of AdVEGF-All6A+, a Replication Deficient Adenovirus Vector Expressing a cDNA/Genomic Hybrid of Human VEGF, to the Ischemic Myocardium of Subjects With Angina Pectoris

NCT04125732 is registered in ClinicalTrials.gov with XyloCor Therapeutics, Inc. as lead sponsor.

NCT NCT04125732
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04125732 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Trial of Direct Administration of AdVEGF-All6A+, a Replication Deficient Adenovirus Vector Expressing a cDNA/Genomic Hybrid of Human VEGF, to the Ischemic Myocardium of Subjects With Angina Pectoris
Lead sponsor
XyloCor Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
January 24, 2020
Completion date
May 30, 2023
Enrollment
41 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

angina refractory, cardiovascular diseases, coronary artery disease, heart diseases, ischemia